February 2014 FDA Recall Bupivacaine Hydrochloride by Hospira Inc.
D-1147-2014 - Presence of Particulate Matter
This Class II drug recall was voluntarily initiated by Hospira Inc. on February 10, 2014 for the product Bupivacaine Hydrochloride. The FDA reported the reason for recall as presence of particulate matter. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-1147-2014
Presence of Particulate Matter: Confirmed customer report of visible particulate embedded in the glass vial.
02-10-2014
03-12-2014
115,500 Vials
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Hospira Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Nationwide
02-01-2017
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Bupivacaine HCl Inj. USP, 0.5% (5 mg/mL), 30 mL Single-dose Preservative Free Vial, Rx Only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1162-02
Batch or Lot Expiration Information
Lot# Lot 25-097-DK; Exp 01/01/2015
